Seven out of every ten patients with non-alcoholic fatty liver disease feel stigmatized
The study, in which Hospital Clínic-IDIBAPS researchers have participated, shows that the perception of this stigma is associated with a deterioratio1
News about Ciberehd
Controlling the dose of a liver transplant rejection drug reduces the risk of developing cancer
A multi-centre study, in which the Clínic-IDIBAPS participated, identified, in nearly 2,500 transplant patients, the main risk factors for the develo1
28 July, World Hepatitis Day: The generalisation of oral antivirals means that admissions due to complications associated with hepatitis C will be anecdotal in a few years
A study conducted by researchers from the Hospital Clínic-IDIBAPS and the CIBEREHD that has been published by the Journal of Hepatology shows that th1
The Clínic-IDIBAPS participates in the international guidelines for the management of ascites, kidney infections and the renal complications of liver cirrhosis
Professionals from the Hospital Clínic-IDIBAPS and CIBEREHD participated in the preparation of the international guidelines produced by the American1
Researchers from the Hospital Clínic-IDIBAPS participate in AASLD’s new guidelines on vascular liver diseases
Researchers from the Hospital Clínic-IDIBAPS and CIBEREHD participated in the new guidelines made by the American Association for the Study of Liver1
Factors associated with satisfactory withdrawal of antiviral treatment in chronic hepatitis B described
Researchers of the IDIBAPS-Hospital Clínic research group Viral, toxic and metabolic liver diseases and CIBEREHD have published a study in the Journa1